Kalaris Therapeutics

Forecast & Rating8 analysts currently cover Kalaris Therapeutics, with about 87.5% giving a positive rating — meaning they expect the stock to rise. The average price target is $18.71, about 631.0% upside from the current price of $2.56. Price targets range from $7.00 to $25.00 — a wide spread, showing clear disagreement over just how much Kalaris Therapeutics can rise. For you, this means most professionals who study Kalaris Therapeutics closely still see room for the stock to rise. Data as of Sep 28, 2026; for reference only and not investment advice.